Company Profile
Codexis Stock Price, News & Analysis
Company overview
Business overview
Codexis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Codexis is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Codexis follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Codexis sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
CDXS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Codexis’s catalysts are enzyme-engineering partnerships, next-gen biocatalyst demand, and any update that shows the platform is still winning in pharma manufacturing and sequencing workflows. Investors will care about whether recurring platform revenue keeps proving the model works.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.